chemotherapy + apatinib

Chemotherapy + apatinib refers to the combination of traditional cytotoxic chemotherapeutic agents with apatinib, a small molecule tyrosine kinase inhibitor that selectively inhibits vascular endothelial growth factor receptor-2 (VEGFR-2). This combination is used primarily in advanced or metastatic cancers such as gastric cancer and non-small cell lung cancer. The rationale for combining these agents is to target both tumor cells directly (chemotherapy) and the tumor vasculature (antiangiogenic effect via VEGFR-2 inhibition), potentially improving efficacy and survival outcomes compared to either treatment alone[1][5][6]. Apatinib has been approved in China for late-line treatment of advanced gastric cancer, but its use in combination with chemotherapy is being explored across multiple lines of therapy[1][5].

Other names

apatinib plus chemotherapyapatinib combined with chemotherapy